TABLE 1.

Characteristics of 96 patients with candidemia

ParameterValue for the parameterP valueb
Total group (n = 96)Survivors (n = 69)aNonsurvivors (n = 27)a
Mean age ± SD (yr)51.9 ± 15.849.7 ± 14.857.7 ± 17.10.039
Age of ≥63 yr (n [%])c25 (26)12 (17.4)13 (48.1)0.002
No. (%) of males sex50 (52)38 (55.1)12 (44.4)0.35
No. (%) of Caucasians56 (58.3)40 (58.0)16 (59.3)0.90
Mean APACHE II score (SD)47 (8)13.7 (5.8)22 (9.7)0.0002
APACHE II score of >23 (n [%])c10 (10.4)2 (2.9)8 (29.6)0.0001
Patient medical profile (n [%])
    Diabetes mellitus32 (33.3)20 (29.0)12 (44.4)0.15
    Renal insufficiencyd22 (22.9)14 (20.3)8 (29.6)0.33
    Neutropeniae11 (11.5)10 (14.5)1 (3.7)0.14
    Transplantation12 (12.5)7 (10.4)5 (18.5)0.27
    Malignancy22 (22.9)19 (27.5)3 (11.1)0.09
    ICU locationf42 (43.8)24 (34.8)18 (66.7)0.005
    Previous surgeryg29 (30.2)19 (27.5)10 (37.0)0.36
    Intubation33 (34.4)18 (26.0)15 (55.6)0.006
    Central venous catheter86 (89.6)61 (88.4)25 (92.3)0.54
    Total parenteral nutrition29 (30.2)20 (29.0)9 (33.3)0.68
    Candida colonization42 (43.8)24 (34.8)18 (66.7)0.005
    Previous antifungal treatmenth23 (23.9)16 (23.2)7 (25.9)0.78
Fluconazole resistance (no. of resistant isolates/no. in group [%])i
    MIC24507/84 (8.3)3/60 (5.0)4/24 (16.7)0.08
    MIC24808/84 (9.5)4/60 (6.7)4/24 (16.7)0.16
    MIC485010/84 (11.9)4/60 (6.7)6/24 (25.0)0.02
    MIC488010/84 (11.9)4/60 (6.7)6/24 (25.0)0.02
Time to fluconazole treatment (mean no. of days [SD])j1.59 (1.2)1.5 (1.3)1.8 (1.1)0.3
Mortality (no. of nonsurvivors/total no. in group [%])k27/96 (28.1)
  • a Mortality data were available for 96 patients.

  • b P values were computed with chi-square or Fisher's exact testing for categorical variables and a student's t test for the variable age.

  • c Based on CART analysis breakpoint value (boldface values).

  • d Defined as serum creatinine of >2.0 mg/dl.

  • e Defined as absolute neutrophil count of <500 at time of culture.

  • f Location at time blood culture was drawn. ICU, intensive care unit.

  • g Surgery within previous 1 month prior to culture.

  • h Receipt of a systemic antifungal agent within 2 weeks prior to first positive Candida blood culture.

  • i Isolates from only 84 of the 96 patients were available for susceptibility testing. Fluconazole was defined as a MIC of ≥64 μg/ml. MICs were read visually after 24 h or 48 h of incubation and determined as 20% (MIC2480, MIC4880) or 50% inhibition (MIC2450, MIC4850) compared with growth control.

  • j Defined as time from culture to start of fluconazole (mean days). Comparison is by a Wilcoxon rank sum test.

  • k Mortality was defined as all-cause death at 6 weeks after first positive Candida blood culture.